Phospho-MEK1(S298)抗体;Phospho-MEK1(S298) Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Phospho-MEK1 (S298) expression in (1) HeLa cell treated with LP lysate; (2) HeLa cell lysate.    

  
  

•  

   

     CircDLST promotes the tumorigenesis and metastasis of gastric cancer by sponging miR-502-5p and activating the NRAS/MEK1/ERK1/2 signaling. -Molecular Cancer    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

Phospho-MEK1(S298) antibodies are specialized tools used to detect the phosphorylation of MEK1 (mitogen-activated protein kinase kinase 1) at serine residue 298. a post-translational modification critical for regulating MEK1 activity and its role in cellular signaling. MEK1 is a central kinase in the MAPK/ERK pathway, which governs processes like cell proliferation, differentiation, and survival. Phosphorylation at S298. located in the proline-rich domain of MEK1. is thought to modulate interactions with upstream regulators (e.g., Raf kinases) or scaffold proteins, influencing subcellular localization or activation dynamics. This site is distinct from the canonical activation loop residues (S218/S222) phosphorylated during MEK1 activation, suggesting a regulatory role in signaling specificity or feedback mechanisms.

Phospho-MEK1(S298) antibodies enable researchers to study MEK1 regulation in response to stimuli (e.g., growth factors, stress) or pathological conditions (e.g., cancer, inflammation). They are widely used in techniques like Western blotting, immunofluorescence, or immunoprecipitation to assess MEK1 activation states, pathway crosstalk, or drug effects. Validation of these antibodies typically includes verifying specificity using knockout cells or phosphorylation-blocking mutants. Dysregulation of MEK1 phosphorylation is implicated in diseases such as cancers with Ras/Raf mutations, making these antibodies valuable for both mechanistic studies and therapeutic development. Proper controls are essential to distinguish S298 phosphorylation from other MEK1 modifications.